Dihydroergocornine API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Dihydroergocornine API 25447-65-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Dihydroergocornine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Dihydroergocornine
- Synonyms:
- 9,10-dihydroergocornine , Dihydroergocornine
- Cas Number:
- 25447-65-8
- DrugBank number:
- DB11273
- Unique Ingredient Identifier:
- IK4C1OC8NE
General Description:
Dihydroergocornine, identified by CAS number 25447-65-8, is a notable compound with significant therapeutic applications. Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects. It is an artificial derivative of the crude extract of ergot and later purified, ergocornine. The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid. Dihydroergocornine presents a formula of 9,10 alpha-dihydro-12'-hydroxy-2',5'alpha-bis(1-methylethyl)-ergotaman-3',6',18-trione. It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to
Indications:
This drug is primarily indicated for: To know more about the approved indications please visit. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Dihydroergocornine undergoes metabolic processing primarily in: The biotransformation of dihydroergocornine occurs via oxidation and cleavage of the proline in the peptide portion of the molecule as well as by the splitting of the amide bond yielding dihydrolysergic acid amide. Some of the derivate metabolites retain the essential ring structure of the ergot alkaloid. To know more about the pharmacokinetics please visit . This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Dihydroergocornine are crucial for its therapeutic efficacy: Dihydroergocornine absorption in man after oral administration is very rapid when compared to the mixture or most of the components. The time to reach maximum plasma concentration or 0.57 ng-eq/ml is 1.4 hours. It presents an absorption half-life of 0.32 hours. The absorption percentage is of about 25% which corresponds to the registered absorption presented in the ergoloid mixture. To know more about the pharmacokinetics please visit . The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Dihydroergocornine is an important consideration for its dosing schedule: To know more about the pharmacokinetics please visit . This determines the duration of action and helps in formulating effective dosing regimens.
Protein Binding:
Dihydroergocornine exhibits a strong affinity for binding with plasma proteins: To know more about the pharmacokinetics please visit . This property plays a key role in the drug's pharmacokinetics and distribution within the body.
Route of Elimination:
The elimination of Dihydroergocornine from the body primarily occurs through: When orally administered, dihydroergocornine is almost completely eliminated via feces. The urinary secretion accounts only for 2.5% of the administered dose. On the other hand, when administered intravenously, the renal excretion can account for approximately 10% of the administered dose. To know more about the pharmacokinetics please visit . Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Volume of Distribution:
Dihydroergocornine is distributed throughout the body with a volume of distribution of: To know more about the pharmacokinetics please visit . This metric indicates how extensively the drug permeates into body tissues.
Clearance:
The clearance rate of Dihydroergocornine is a critical factor in determining its safe and effective dosage: No pharmacokinetic related to the clearance rate was found in current literature. It reflects the efficiency with which the drug is removed from the systemic circulation.
Pharmacodynamics:
Dihydroergocornine exerts its therapeutic effects through: It is reported that dihydroergocornine administration, in non-toxic doses, presents sympatholytic and hypotensive properties which are observed as a significantly decreased mean arterial pressure. In the brain, the activity of dihydroergocornine was observed as a decrease in cerebral blood flow, cerebral vascular resistance and oxygen uptake. The effect in the brain seems to allow a cerebral metabolic homeostasis. To know more about the pharmacology please visit. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Dihydroergocornine functions by: The mechanism of action by which dihydroergocornine exerts its effects are not entirely defined. However, it is reported that dihydroergocornine has central and peripheral effects. The fall in blood pressure seems to be related to the stimulation of the vasodilator center. It has been demonstrated that dihydroergocornine possesses potent adrenolytic and sympathicolytic actions. The effect of dihydroergocornine is related to the inhibitory effect against the serotonin and noradrenaline receptors in which dihydroergocornine seems to be very potent against a stimulation-induced noradrenaline overflow. It also presents a stimulatory effect in arterial and venous smooth muscle when administered at slightly higher concentrations than the necessary for the inhibitory effect. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Classification:
Dihydroergocornine belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives, classified under the direct parent group Ergopeptines. This compound is a part of the Organic compounds, falling under the Alkaloids and derivatives superclass, and categorized within the Ergoline and derivatives class, specifically within the Lysergic acids and derivatives subclass.
Categories:
Dihydroergocornine is categorized under the following therapeutic classes: Agents that produce hypertension, Alkaloids, Cytochrome P-450 CYP3A Substrates, Cytochrome P-450 CYP3A4 Substrates, Cytochrome P-450 CYP3A4 Substrates (strength unknown), Cytochrome P-450 Substrates, Dopamine Agents, Dopamine Agonists, Ergot Alkaloids and Derivatives, Ergot-derivative Dopamine Receptor Agonists, Ergotamines, Heterocyclic Compounds, Fused-Ring, Neurotransmitter Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Dihydroergocornine include:
- Melting Point: 187 ºC
- Boiling Point: Decomposes
- logP: 2.33
Dihydroergocornine is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
